Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib versus teriflunomide in relapsing multiple sclerosis
2020-005899-36Phase 3Active
- Sponsor
- Novartis
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Started Nov 2021; status: active.
02
Drugs
remibrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2020-005899-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005899-36.